Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Phase II development of LY-3337641 for rheumatoid arthritis ended

Feb. 20, 2018

Bristol-Myers Squibb identifies novel Toll-like receptor 7/8/9 antagonists

Feb. 19, 2018

RCGD-423 prevents articular cartilage degeneration and promotes repair in vivo

Feb. 19, 2018

Novartis studies LRX-712 in patients with osteoarthritis

Feb. 15, 2018

EMA grants ATMP classification to Regeneus' Progenza

Feb. 15, 2018

Therachon starts first-in-human trial of TA-46 for achondroplasia

Feb. 15, 2018

Phase III trials of peficitinib in rheumatoid arthritis meet primary endpoints

Feb. 9, 2018

Symic Biomedical reports MODIFY2 phase II trial results of SB-061 for knee osteoarthritis

Feb. 8, 2018

YL Biologics reports successful completion of phase III trial of etanercept biosimilar YLB-113

Feb. 8, 2018

Lilly identifies new JAK1 inhibitors

Feb. 6, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.